New COVID-19 Saliva Test Makes Testing Far Easier for All Ages
14.7.2021 10:00:00 EEST | Business Wire | Press release
UK company Intelligent Fingerprinting, manufacturers of the world’s first and only fingerprint sweat drug test, has now developed an easy-to-use saliva-based lateral flow test for the rapid detection of the COVID-19 antigen. In contrast to existing COVID-19 tests that require unpleasant, invasive nose and throat swabs, Intelligent Fingerprinting’s test uses a simple swab to collect a saliva sample just from the inside of the cheek. The test strip is deliberately simple in design and engineered to keep plastic usage to a minimum - with none of the plastic casing present that is usually associated with lateral flow tests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005243/en/
New COVID-19 saliva test makes testing far easier for all ages. How it works: A swab is used to collect the saliva sample from the inside of the lower cheek, which is then mixed with a reagent buffer that has been pre-added to the collection tube in order to release the virus. The screening test is performed by inserting the tip of the VSS-GP test strip into the sample, providing a positive or negative result at 20 minutes. No instrumentation is required. The test uses gold immunonanoparticle technology to enable the visual detection of bound antigen via a control line and a red line on the test strip when a saliva sample is positive for the SARS-CoV-2 antigen. (Photo: Business Wire)
The Intelligent Fingerprinting COVID-19 test’s easy saliva sample collection makes it particularly suitable for testing more vulnerable people and children. It facilitates frequent testing across a range of applications including schools, workplaces, public events, care homes, healthcare, airports and prisons. Test results are available in 20 minutes – a third quicker than most current nose and throat lateral flow tests.
“Almost everyone who has taken a nose or throat swab to test for COVID-19 knows just how unpleasant they can be. In developing our new COVID-19 saliva test, we have successfully combined the benefits of much simpler sample collection with high levels of accuracy using our existing technology,” explained Intelligent Fingerprinting’s Executive Chairman Philip Hand.
“The introduction of our new COVID-19 test involved rapid design, development and manufacture within the UK over a ten-month period. Manufacturing capacity at our Cambridge plant, utilising existing equipment and ISO 13485 quality control, is ready to support the production of millions of tests per month, and we also anticipate we will be working with existing and new distribution partners to make this test available across multiple markets,” he added.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005243/en/
Contact information
cheryl.billson@commacomms.com
+44(0)7791 720460
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz Delivers Record Nine-month Result of 14.1 Billion Euros and Raises 2026 Outlook12.11.2026 08:06:00 EET | Press release
3Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111915059/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 44.4 billion euros, an internal growth of 3.0 percent1. Excellent contribution from Asset Management and good internal growth in Property-Casualty. Operating profit rises 6.2 percent to 4.7 billion euros, driven by an outstanding result from the Asset Management segment, attributable to higher business volume and margins, and a strong contribution from Life/Health. Shareholders’ core net income increases 1.2 percent to 2.9 billion euros. Adjusted for offsetting measures following the sale of the stake in our Indian JVs, underlying growth is 3 percent. 9M 2026 Total business volume at 143.0 billion euros, an internal growth of 3.8 percent 1 , driven by excellent growth in Asset Management and good internal growth in Property-Casualty. Operating profit rises 7.8 percent to 14.1 bil
LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 07:30:00 EET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing
Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 21:18:00 EET | Press release
Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo
Angel Aligner Unveils Six Innovations for 202711.11.2026 18:23:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bindu Saran, VP of Product Strategy, added: “Angel was founded by orthodontic profe
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom